ArticleMedicine2026
Immune cell phenotypes in the context of diabetic nephropathy: A Mendelian randomization analysis.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
To clarify whether specific immune cell phenotypes exert a causal influence on diabetic nephropathy (DN), we conducted a Mendelian randomization (MR) investigation using large-scale genetic datasets. Summary-level data for immune cell traits and DN were obtained from recent genome-wide association studies and the FinnGen consortium. Genetic instruments were selected under the core MR assumptions, ensuring strong relevance and minimal confounding. The inverse-variance weighted approach served as the primary analytical framework. Complementary analyses, including MR-Egger regression, Cochran Q test, and leave-one-out procedures, were performed to detect horizontal pleiotropy, assess heterogeneity, and evaluate the stability of the findings. Genetically predicted increases in several immune cell phenotypes were associated with higher genetic susceptibility to DN, including CD25 on IgD- CD38dim (odds ratio [OR]: 1.153, P = .026), CD8dim AC (OR: 1.144, P = .045), HLA DR on CD33br HLA DR+ CD14- (OR: 1.142, P < .001), CD39+ CD8br %CD8br (OR: 1.094, P = .047), and CD25hi CD45RA+ CD4 not Treg %T cell (OR: 1.051, P = .041). Conversely, higher SSC-A on CD4+ cells was associated with lower genetic susceptibility to DN (OR: 0.385, P < .001). No evidence of horizontal pleiotropy was detected (P ≥ .05). Cochran Q indicated no significant heterogeneity. Sensitivity analyses confirmed the robustness of all associations. This MR analysis suggests that HLA DR on CD33br HLA DR+ CD14- is associated with increased genetic susceptibility to DN, whereas SSC-A on CD4+ is associated with decreased susceptibility. These findings offer genetic evidence of immune involvement in DN susceptibility and warrant further validation and investigation to clarify mechanisms and relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.